ArticleEuropean journal of clinical pharmacology2025
Pharmacogenomics-guided treatment versus conventional treatment in patients with Schizophrenia: Evaluation of medication adherence and switching rate.
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "pharmacogenomics-guided treatment versus conventional treatment in patients with schizophrenia: evaluation of medication adherence and switching rate".European journal of clinical pharmacology · 2026Article
- The clinical value of pharmacogenomics in the pharmacotherapy of common psychiatric disorders: a macroscopic analysis based on real-world data.BMC psychiatry · 2026Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe main objective of this study was to systematically evaluate the effectiveness of pharmacogenomics-guided treatment (PGxT) and treatment-as-usual (TAU) in schizophrenia management through two key indicators: medication adherence and antipsychotic switching rate.
methodsThe study cohort comprised individuals with schizophrenia who were hospitalized between April 2022 and March 2024. The cohort was stratified into two groups: the PGxT and TAU. To address potential confounding between the groups, propensity score matching (PSM) was applied. The primary outcome measures were the proportions of patients with good medication adherence (≥ 80%) at three and six months after discharge and the antipsychotic switching rate.
resultsAmong the 420 patients in the PGxT and TAU groups obtained through propensity score matching, the proportions of patients with good medication adherence (≥ 80%) was 49.76% at three months and 33.10% at six months, with a significant difference between the follow-up periods (P < 0.001). During the three-month observation period, the proportion of patients demonstrating good adherence were significantly different (55.24% in PGxT group vs. 44.29% in TAU group; P = 0.032). The difference was also significant after six months (44.76% in PGxT group vs. 21.43% in TAU group; P < 0.001). Furthermore, the proportion of antipsychotic switching rate was lower in the PGxT group (25.71%) than in the TAU group (41.90%) (P < 0.001).
conclusionThis study observed an association between PGxT and higher adherence as well as lower medication switching rate in patients with schizophrenia, which suggests potential clinical utility of PGx testing.
Indexed as
Identifiers
40478260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.